In 2024, the Colorado Prescription Drug Affordability Review Board declared Enbrel unaffordable, and last year it set an ...

Novartis has launched two trials pitching Cosentyx head-to-head with AbbVie’s Humira and one of its own biosimilars in a bid to increase its presence in a highly competitive market. Cosentyx ...

Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in ...

The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.

The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL-17 ...

Celltrion said Friday its second-quarter operating profit increased 77 percent year-on-year to 430 billion won ($278.14 ...

Celltrion posted record second-quarter earnings, with sales of 1.3 trillion won ($836 million) and operating profit of 430 ...

Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

M upfront, up to $1.8B milestones, and what it signals for NVS amid patent cliffs. Click for this look at the deal.

DENVER — Colorado’s first attempt to cap the price of an unaffordable prescription drug has been blocked by a judge, marking the first legal hurdle as the state tries to rein in pharmaceutical ...